HOPE Therapeutics, Inc. and NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Announce Signing of Binding Letter of Intent with Neurospa TMS Holdings, LLC for Expansion of its Planned International Network of Interventional Psychiatry Clinics
NRx Pharmaceuticals (NASDAQ:NRXP) announced that its wholly-owned subsidiary, HOPE Therapeutics, has signed a binding Letter of Intent to acquire a majority stake in Neurospa TMS Holdings, which operates six interventional psychiatry clinics on Florida's Gulf Coast.
Neurospa, which is currently revenue-generating and EBITDA positive, provides comprehensive psychiatric care including Ketamine Infusion Therapy, Transcranial Magnetic Stimulation (TMS), and Spravato® treatments, along with traditional psychiatry and talk therapy. These services target patients with depression, suicidality, PTSD, anxiety, and related disorders.
The acquisition is expected to be accretive to HOPE's revenue projections for 2025. The deal completion is contingent on financial audits, definitive agreements, and standard closing conditions.
NRx Pharmaceuticals (NASDAQ:NRXP) ha annunciato che la sua controllata interamente posseduta, HOPE Therapeutics, ha firmato una lettera di intenti vincolante per acquisire una partecipazione di maggioranza in Neurospa TMS Holdings, che gestisce sei cliniche di psichiatria interventistica sulla costa del Golfo della Florida.
Neurospa, attualmente in grado di generare entrate e con EBITDA positivo, offre un'assistenza psichiatrica completa che include terapia con infusione di ketamina, stimolazione magnetica transcranica (TMS) e trattamenti con Spravato®, insieme a psichiatria tradizionale e terapia dialogica. Questi servizi sono destinati a pazienti con depressione, suicidio, PTSD, ansia e disturbi correlati.
Si prevede che l'acquisizione sarà accrescitiva per le proiezioni di entrate di HOPE per il 2025. Il completamento dell'affare è soggetto a audit finanziari, accordi definitivi e condizioni di chiusura standard.
NRx Pharmaceuticals (NASDAQ:NRXP) anunció que su filial de propiedad total, HOPE Therapeutics, ha firmado una carta de intención vinculante para adquirir una participación mayoritaria en Neurospa TMS Holdings, que opera seis clínicas de psiquiatría intervencionista en la costa del Golfo de Florida.
Neurospa, que actualmente genera ingresos y es positiva en EBITDA, proporciona atención psiquiátrica integral que incluye terapia de infusión de ketamina, estimulación magnética transcraneal (TMS) y tratamientos con Spravato®, junto con psiquiatría tradicional y terapia conversacional. Estos servicios están dirigidos a pacientes con depresión, suicidio, PTSD, ansiedad y trastornos relacionados.
Se espera que la adquisición sea positiva para las proyecciones de ingresos de HOPE para 2025. La finalización del acuerdo está sujeta a auditorías financieras, acuerdos definitivos y condiciones de cierre estándar.
NRx Pharmaceuticals (NASDAQ:NRXP)는 자회사인 HOPE Therapeutics가 Neurospa TMS Holdings의 대다수 지분을 인수하기 위한 구속력 있는 의향서를 체결했다고 발표했습니다. Neurospa는 플로리다의 걸프 코스트에 있는 6개의 개입 정신과 클리닉을 운영하고 있습니다.
Neurospa는 현재 수익을 창출하고 EBITDA가 긍정적이며, 케타민 주입 요법, 경두개 자기 자극(TMS), Spravato® 치료를 포함한 포괄적인 정신과 치료를 제공하며, 전통적인 정신과 및 대화 요법도 제공합니다. 이러한 서비스는 우울증, 자살, PTSD, 불안 및 관련 장애가 있는 환자를 대상으로 합니다.
이번 인수는 HOPE의 2025년 수익 예측에 긍정적인 영향을 미칠 것으로 예상됩니다. 거래 완료는 재무 감사, 최종 계약 및 표준 종료 조건에 따라 달라집니다.
NRx Pharmaceuticals (NASDAQ:NRXP) a annoncé que sa filiale entièrement détenue, HOPE Therapeutics, a signé une lettre d'intention contraignante pour acquérir une participation majoritaire dans Neurospa TMS Holdings, qui gère six cliniques de psychiatrie interventionnelle sur la côte du Golfe de Floride.
Neurospa, qui génère actuellement des revenus et est positif en EBITDA, offre des soins psychiatriques complets, y compris thérapie par infusion de kétamine, stimulation magnétique transcrânienne (TMS) et traitements avec Spravato®, ainsi que de la psychiatrie traditionnelle et de la thérapie par la parole. Ces services ciblent les patients souffrant de dépression, de suicides, de PTSD, d'anxiété et de troubles connexes.
L'acquisition devrait être bénéfique pour les prévisions de revenus de HOPE pour 2025. La finalisation de l'accord est soumise à des audits financiers, à des accords définitifs et à des conditions de clôture standard.
NRx Pharmaceuticals (NASDAQ:NRXP) gab bekannt, dass ihre hundertprozentige Tochtergesellschaft, HOPE Therapeutics, eine verbindliche Absichtserklärung zur Übernahme einer Mehrheitsbeteiligung an Neurospa TMS Holdings unterzeichnet hat, die sechs intervenierende psychiatrische Kliniken an der Golfküste Floridas betreibt.
Neurospa, das derzeit Einnahmen generiert und EBITDA-positiv ist, bietet umfassende psychiatrische Betreuung, einschließlich Ketamin-Infusionstherapie, transkranielle Magnetstimulation (TMS) und Spravato®-Behandlungen sowie traditionelle Psychiatrie und Gesprächstherapie. Diese Dienstleistungen richten sich an Patienten mit Depressionen, Suizidalität, PTSD, Angstzuständen und verwandten Störungen.
Die Übernahme wird voraussichtlich positiv zu den Umsatzprognosen von HOPE für 2025 beitragen. Der Abschluss des Deals hängt von finanziellen Prüfungen, endgültigen Vereinbarungen und standardmäßigen Abschlussbedingungen ab.
- Acquisition of revenue-generating and EBITDA positive clinics
- Immediate expansion into six operational locations
- Expected to be accretive to revenue projections for 2025
- Diversified treatment portfolio including FDA-approved procedures
- Transaction still subject to financial audits and closing conditions
- Acquisition costs and terms not disclosed
Insights
NRXP's strategic expansion of its HOPE Therapeutics subsidiary through the planned acquisition of a majority stake in Neurospa represents a significant development in its interventional psychiatry business. This acquisition brings six established clinics on Florida's Gulf Coast into NRXP's network, immediately expanding HOPE's physical footprint with facilities that are both revenue-generating and EBITDA-positive.
The move strategically diversifies NRXP's approach in mental health treatment by incorporating Neurospa's comprehensive service model, which combines Ketamine Infusion Therapy, Transcranial Magnetic Stimulation (TMS), and Spravato® with traditional psychiatric approaches. This integrated care approach addresses multiple treatment pathways for depression, PTSD, anxiety, and related disorders – potentially capturing broader patient populations.
By acquiring established clinics rather than building from scratch, NRXP gains immediate market presence and operational expertise in the interventional psychiatry space, accelerating HOPE's growth timeline. The retention of Neurospa's existing clinical team preserves continuity of care and operational knowledge, crucial factors in healthcare services integration.
While still subject to final agreements and closing conditions, this transaction signals NRXP's commitment to establishing HOPE Therapeutics as a significant player in the interventional psychiatry market, with plans for further Florida network expansion evident in the announcement.
The binding LOI to acquire a majority stake in Neurospa represents a potentially value-enhancing transaction for NRXP shareholders. The deal structure, involving a combination of cash and equity, allows NRXP to leverage its balance sheet while preserving capital for other initiatives.
Particularly noteworthy is that the acquisition targets an EBITDA-positive business, suggesting immediate contribution to NRXP's financial performance without the typical drain of integrating unprofitable operations. The announcement explicitly states the acquisition will be accretive to HOPE's 2025 revenue projections, indicating management expects meaningful financial contribution.
For a company with NRXP's market capitalization (
Investors should note this transaction remains contingent on financial audits, definitive agreements, and standard closing conditions – typical caveats that introduce execution risk. While specific financial terms remain undisclosed, the strategic addition of six revenue-generating facilities strengthens NRXP's commercial foundation and potentially accelerates its path to improved financial performance.
- Neurospa currently operates six interventional psychiatry clinics on
Florida's Gulf Coast - HOPE to acquire majority interest in Neurospa for a combination of cash and equity
- Neurospa clinics deliver a full range of interventional psychiatry services, including Ketamine, Spravato® and Transcranial Magnetic Stimulation (TMS) to patients with severe depression and related conditions
- Acquisition to be accretive to HOPE revenue projections for 2025
Neurospa leverages state-of-the-art interventional psychiatry procedures, including Ketamine Infusion Therapy, Transcranial Magnetic Stimulation (TMS), and Spravato®, augmented by traditional psychiatry and talk therapy to provide a full continuum of care for people with depression, suicidality, PTSD, anxiety, and related disorders. TMS is an FDA-approved procedure in which focused electromagnetic treatment has been demonstrated to reduce symptoms of depression. Ketamine and Spravato® are similarly known to reduce symptoms of depression and both forms of treatment are increasingly used in an additive manner.
Neurospa provides a physician-led, welcoming spa-like environment that puts patient's needs and comfort first. Neurospa's outstanding team of dedicated professionals are to become key members of the HOPE team upon closing of the transaction.
"Neurospa was founded with the mission to provide TMS therapy for patients in the
"We are thrilled to welcome the Neurospa team to the HOPE network and look forward to the contribution they will continue to make to their patients and to the expansion of the HOPE network statewide," said Jonathan Javitt, MD MPH and Matthew Duffy, Co-CEOs of HOPE Therapeutics.
The intended acquisition of Neurospa is subject to the completion of financial audits, execution of definitive agreements, and the satisfaction of standard closing conditions.
About HOPE Therapeutics, Inc.
HOPE Therapeutics, Inc. (www.hopetherapeutics.com) is a healthcare delivery company currently developing a best-in-class network of interventional psychiatry clinics to offer psychedelic medications, including ketamine and Spravato®, combined with Transcranial Magnetic Stimulation (TMS) and other lifesaving, neuroplastic therapies to patients with suicidal depression and related disorders, together with a digital therapeutic-enabled platform designed to augment and preserve the clinical benefit of NMDA-targeted drug therapy.
About NRx Pharmaceuticals, Inc.
NRx Pharmaceuticals is a clinical-stage biopharmaceutical company developing therapeutics based on its NMDA platform for the treatment of central nervous system disorders, specifically suicidal bipolar depression, chronic pain, and PTSD. The Company is developing NRX-101, an FDA-designated investigational Breakthrough Therapy for suicidal treatment-resistant bipolar depression and chronic pain. NRx plans to file an NDA for Accelerated Approval for NRX-101 in patients with bipolar depression and suicidality or akathisia.
NRx recently announced initiation of filing a New Drug Application for NRX-100 (IV ketamine) for the treatment of suicidal depression, based on results of well-controlled clinical trials conducted under the auspices of the US National Institutes of Health and newly obtained data from French health authorities, licensed under data sharing agreements. NRx was awarded Fast Track Designation for development of ketamine (NRX-100) by the US FDA as part of a protocol to treat patients with acute suicidality.
Notice Regarding Forward-Looking Statements
The information contained herein includes forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and Section 27A of the Securities Act of 1933, as amended. These statements include, among others, statements regarding the satisfaction of closing conditions necessary to consummate the acquisition of Kadima, Neurospa and Dura, and obtaining financing necessary to consummate the acquisitions. Forward-looking statements generally include statements that are predictive in nature and depend upon or refer to future events or conditions, and include words such as "may," "will," "should," "would," "expect," "plan," "believe," "intend," "look forward," and other similar expressions among others. These statements relate to future events or to the Company's future financial performance, and involve known and unknown risks, uncertainties and other factors that may cause the Company's actual results to be materially different from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. You should not place undue reliance on forward-looking statements since they involve known and unknown risks, uncertainties and other factors which are, in some cases, beyond the Company's control and which could, and likely will, materially affect actual results, levels of activity, performance or achievements. Any forward-looking statement reflects the Company's current views with respect to future events and is subject to these and other risks, uncertainties and assumptions relating to the Company's operations, results of operations, growth strategy, liquidity, Hope Therapeutic's ability to consummate the acquisitions of providers for its national network, the Company's ability to raise adequate capital to fund such acquisitions, and the Company's ability to spin-off Hope Therapeutics. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is set forth in the Company's most recent Annual Report on Form 10-K and other filings with the Securities and Exchange Commission. Investors and security holders are urged to read these documents free of charge on the SEC's website at http://www.sec.gov. Except as may be required by applicable law, The Company assumes no obligation to publicly update or revise these forward-looking statements for any reason, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, whether as a result of new information, future events or otherwise.
For further information:
Matthew Duffy
Co-Chief Executive Officer, HOPE Therapeutics, Inc.
Chief Business Officer, NRx Pharmaceuticals, Inc.
mduffy@nrxpharma.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/hope-therapeutics-inc-and-nrx-pharmaceuticals-inc-nasdaqnrxp-announce-signing-of-binding-letter-of-intent-with-neurospa-tms-holdings-llc-for-expansion-of-its-planned-international-network-of-interventional-psychiatry-clini-302408763.html
SOURCE NRx Pharmaceuticals, Inc.
FAQ
What is the strategic importance of NRXP's acquisition of Neurospa TMS Holdings?
What treatment services does Neurospa offer that NRXP will acquire?
How will the Neurospa acquisition impact NRXP's financial performance?
What conditions are treated at the Neurospa clinics being acquired by NRXP?
